

8 March 2023

Botanix To Host Investor Webinar

Perth, Australia 8 March 2023: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to advise that it will be hosting an investor webinar this Thursday 9 March 2023 (AU).

A mid-cycle review meeting with the Food and Drug Administration (FDA) for the Company’s lead product, Sofpironium Bromide, remains on track for Q1 CY23 - an important milestone for the Company. The webinar will be hosted by Gautam Aggarwal, a Partner with Triangle Insights Group, who has conducted market research in relation to the Company’s Sofpironium Bromide product for hyperhidrosis.

More details will be available, along with a copy of the presentation to be used as part of the webinar which will be released Thursday morning before the webinar.

WEBINAR PRESENTERS:

- Triangle Insights Group Partner and sector commentator, Gautam Aggarwal
- Botanix Chief Operating Officer, Dr Howie McKibbon.
- Botanix Executive Director, Matt Callahan

WHEN: 12 midday AEDT, 9 March 2023 (AU)

WHAT: Triangle Insights will be outlining the results from some recent market research conducted in relation to the hyperhidrosis market in the context of the planned approval of Sofpironium Bromide.

REGISTER YOUR ATTENDANCE:

https://us02web.zoom.us/webinar/register/WN_HcbwrcHpRS2DJFXToTVrhA

SUBMIT A QUESTION: If you would like to submit a question ahead of this event, please email:

hhowlett@we-worldwide.com

Release authorised by

Vince Ippolito
Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is committed to the development of novel treatments for a range of common skin diseases. The Company has a mature dermatology pipeline with its first product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis, filed for FDA approval in Q3 CY2022 with approval expected in Q3 2023. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis.

Botanix leverages its proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.